Symptomatic recovery and pharmacological management in a clinical cohort with peripartum cardiomyopathy

Aim: We aimed to characterize the clinical course with focus on pharmacological management of peripartum cardiomyopathy (PPCM) in Sweden.

Methods: Twenty-four consecutive patients were retrospectively identified among women presenting with PPCM in Western Sweden. Of these, 14 had concomitant preeclampsia. There was only one fatality. The mean (standard deviation) left ventricular ejection fraction (LVEF) at diagnosis was 35.0?±?9.9%. Ten women, 47.6%, required intensive care unit (ICU) admission. All patients received β-blockers (BB) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACE-I/ARB), which were tapered off over a mean/median period of 3.3/2.5?years with only one case of worsening heart failure. The mean follow-up for medication was 7.9?±?2.6?years. Early and late/non-recovery was defined as New York Heart Association (NYHA) functional class I and NYHA II–IV at one?year, respectively. Late recovery was associated with larger LVEDD at diagnosis (56.8 versus 62.4?mm) was associated with late recovery, p?=?.02.

Results and conclusions: PPCM had an overall good prognosis in this cohort. Left ventricular dilation at presentation was a predictor of worse prognosis. Concurrent preeclampsia was common, but was associated with better prognosis. Medication was safely discontinued in 75% of patients.